Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Structural Heart Disease
What is your preferred single antiplatelet agent to use when combined with a DOAC for a patient with atrial fibrillation who is now 1 year post-TAVR?
Related Questions
Are there specific types of bioprosthetic valves that would make you inclined to choose VKA in lieu of a DOAC for systemic anticoagulation several months post-valve replacement?
In a patient with severe TR, when is the best time to start thinking about T-TEER?
In patients with contraindications to TEE and poor windows for TTE, what is the next best test to look for PFO?
How would you approach anticoagulation management and consideration for PFO closure in patients with acute lower extremity DVTs involving the proximal deep veins and findings concerning for PFO on echocardiogram?
Which anticoagulant (DOAC or Warfarin) would you recommend in the case of a 70-year-old male with persistent atrial fibrillation and history of rheumatic mitral stenosis now status post bioprosthetic MVR?
How would you approach the INR goal in a patient with mechanical aortic valve and high bleeding risk factors like immune thrombocytopenia, AV malformations and recurrent GI bleeds, etc.?
Are there instances where TAVR should be considered for patients with moderate AS and HFrEF?
What is the best approach to asymptomatic severe primary tricuspid regurgitation when imaging begins to show RV enlargement?
What would be your approach for the management of asymptomatic, severe AS with a peak velocity of 5 m/s in an otherwise physically active patient in their mid-90s without significant co-morbidities?
In patients with moderate calcific mitral stenosis, possible HFpEF and dyspnea on exertion, how would you differentiate the etiology of the symptoms?
